Picton Mahoney Asset Management Makes New $125,000 Investment in Glaukos Co. (NYSE:GKOS)

Picton Mahoney Asset Management purchased a new position in Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 840 shares of the medical instruments supplier’s stock, valued at approximately $125,000.

Other large investors also recently modified their holdings of the company. IFP Advisors Inc bought a new stake in Glaukos in the fourth quarter worth approximately $43,000. Asset Planning Inc bought a new position in Glaukos during the fourth quarter worth $90,000. Harvest Fund Management Co. Ltd grew its holdings in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the period. SBI Securities Co. Ltd. bought a new stake in Glaukos in the fourth quarter valued at $153,000. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 807 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,744 shares of company stock worth $2,504,131. 6.40% of the stock is owned by company insiders.

Glaukos Stock Performance

GKOS stock opened at $102.43 on Monday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.79 billion, a PE ratio of -35.69 and a beta of 0.99. The business has a 50 day moving average of $140.86 and a 200-day moving average of $137.69. Glaukos Co. has a 12-month low of $85.04 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. As a group, sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wells Fargo & Company boosted their target price on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus boosted their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Needham & Company LLC raised their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.